Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
January 23, 2020
As middle income countries transition from donor support and increasingly use domestic funds to finance health programmes that have previously received substantial external aid, it is imperative that they build and use Health Technology Assessment capacities so that they can prioritise inv...
Blog Post
December 02, 2019
As countries reaffirm their commitments to achieving Universal Health Coverage, governments face extraordinary pressure to allocate scarce resources in a publicly justifiable manner. The growing list of available health interventions and increasing demand for health services mean that toug...
Blog Post
November 05, 2019
Though there are various definitions of HTA, and different approaches for considering evidence on clinical effectiveness, economics, social values, and ethics, there is a universal emphasis on generating transparent and evidence-informed recommendations for health coverage decisions.
...
Blog Post
October 31, 2019
Policymakers and clinicians in global health often face considerable uncertainty when making decisions. While statistical uncertainty can be accounted for by placing confidence intervals on the estimated impacts of different policies and treatment regimes, “deep” uncertainty poses a more...
CGD NOTES
September 24, 2019
Global health interventions, like many public policies, are rife with uncertainty. Will a program, such as a malaria prevention strategy that looks strong on paper, work as intended? Will a new technology, such as a specific drug or device that appears effective in clinical trial settings, work in p...
CGD NOTES
April 08, 2019
Criticising cancer medicine pricing as too high is what football fans know as an "open goal"—a target that is hard to miss. Yet somehow the World Health Organization Technical Report on Cancer Pricing manages to do just that with a paper to the WHO Executive Board calling for pri...
Blog Post
November 13, 2018
Back in February, the US Council of Economic Advisers issued a white paper on drug pricing implying that other rich countries should stop “free riding” off American innovation by negotiating drug prices to unfairly low levels after the US fronts the research and development cos...
POLICY PAPERS
March 09, 2018
As developing nations are increasingly adopting economic evaluation as a means of informing their own investment decisions, new questions emerge. The right answer to the question “which perspective?” is the one tailored to these local specifics. We conclude that there is no one-size-fits-all an...
CGD NOTES
November 08, 2017
With aid budgets shrinking and even low-income countries increasingly faced with cofinancing requirements, this is the right time for global health funders such as the Global Fund and their donors to formally introduce Health Technology Assessment (HTA), both at the central operations level and at t...
Blog Post
March 22, 2017
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, howe...